|
1
|
Epstein MA, Achong BG and Barr YM: Virus
particles in cultured lymphoblasts from Burkitt’s lymphoma. Lancet.
1:702–703. 1964.PubMed/NCBI
|
|
2
|
Taylor GS and Blackbourn DJ: Infectious
agents in human cancers: lessons in immunity and immunomodulation
from gammaherpesviruses EBV and KSHV. Cancer Lett. 305:263–278.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mounier N, Spina M and Gisselbrecht C:
Modern management of non-Hodgkin lymphoma in HIV-infected patients.
Br J Haematol. 136:685–698. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Re D, Thomas RK, Behringer K and Diehl V:
From Hodgkin disease to Hodgkin lymphoma: biologic insights and
therapeutic potential. Blood. 105:4553–4560. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chaturvedi MM, Sung B, Yadav VR, Kannappan
R and Aggarwal BB: NF-κB addiction and its role in cancer: ‘one
size does not fit all’. Oncogene. 30:1615–1630. 2011.
|
|
6
|
Liebowitz D: Epstein-Barr virus and a
cellular signaling pathway in lymphomas from immunosuppressed
patients. N Engl J Med. 338:1413–1421. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Peng J, Yuan J-P, Wu C-F and Wang J-H:
Fucoxanthin, a marine carotenoid present in brown seaweeds and
diatoms: metabolism and bioactivities relevant to human health. Mar
Drugs. 9:1806–1828. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim K-N, Heo S-J, Yoon W-J, Kang S-M, Ahn
G, Yi T-H and Jeon Y-J: Fucoxanthin inhibits the inflammatory
response by suppressing the activation of NF-κB and MAPKs in
lipopolysaccharide-induced RAW 264.7 macrophages. Eur J Pharmacol.
649:369–375. 2010.PubMed/NCBI
|
|
9
|
Zhang C, Ao Z, Seth A and Schlossman SF: A
mitochondrial membrane protein defined by a novel monoclonal
antibody is preferentially detected in apoptotic cells. J Immunol.
157:3980–3987. 1996.PubMed/NCBI
|
|
10
|
Antalis TM and Godbolt D: Isolation of
intact nuclei from hematopoietic cell types. Nucleic Acids Res.
19:43011991. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vallabhapurapu S and Karin M: Regulation
and function of NF-κB transcription factors in the immune system.
Annu Rev Immunol. 27:693–733. 2009.
|
|
12
|
Pahl HL: Activators and target genes of
Rel/NF-κB transcription factors. Oncogene. 18:6853–6866. 1999.
|
|
13
|
Grossmann M, O’Reilly LA, Gugasyan R,
Strasser A, Adams JM and Gerondakis S: The anti-apoptotic
activities of Rel and RelA required during B-cell maturation
involve the regulation of Bcl-2 expression. EMBO J. 19:6351–6360.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wäldele K, Silbermann K, Schneider G,
Ruckes T, Cullen BR and Grassmann R: Requirement of the human
T-cell leukemia virus (HTLV-1) tax-stimulated HIAP-1 gene
for the survival of transformed lymphocytes. Blood. 107:4491–4499.
2006.PubMed/NCBI
|
|
15
|
Stehlik C, de Martin R, Kumabashiri I,
Schmid JA, Binder BR and Lipp J: Nuclear factor (NF)-κB-regulated
X-chromosome-linked iap gene expression protects endothelial
cells from tumor necrosis factor α-induced apoptosis. J Exp Med.
188:211–216. 1998.
|
|
16
|
Iwanaga R, Ohtani K, Hayashi T and
Nakamura M: Molecular mechanism of cell cycle progression induced
by the oncogene product Tax of human T-cell leukemia virus type I.
Oncogene. 20:2055–2067. 2001. View Article : Google Scholar
|
|
17
|
Huang Y, Ohtani K, Iwanaga R, Matsumura Y
and Nakamura M: Direct trans-activation of the human cyclin D2 gene
by the oncogene product Tax of human T-cell leukemia virus type I.
Oncogene. 20:1094–1102. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hinz M, Krappmann D, Eichten A, Heder A,
Scheidereit C and Strauss M: NF-κB function in growth control:
regulation of cyclin D1 expression and
G0/G1-to-S-phase transition. Mol Cell Biol.
19:2690–2698. 1999.
|
|
19
|
Jost PJ and Ruland J: Aberrant NF-κB
signaling in lymphoma: mechanisms, consequences, and therapeutic
implications. Blood. 109:2700–2707. 2007.
|
|
20
|
Kimura N, Miyakawa Y, Kohmura K, Umezawa
K, Ikeda Y and Kizaki M: Targeting NF-κB and induction of apoptosis
by novel NF-κB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in
Burkitt lymphoma cells. Leuk Res. 31:1529–1535. 2007.
|
|
21
|
Küppers R: Molecular biology of Hodgkin
lymphoma. Hematology Am Soc Hematol Educ Program. 491–496.
2009.
|
|
22
|
Sugawara T, Baskaran V, Tsuzuki W and
Nagao A: Brown algae fucoxanthin is hydrolyzed to fucoxanthinol
during absorption by Caco-2 human intestinal cells and mice. J
Nutr. 132:946–951. 2002.PubMed/NCBI
|
|
23
|
Asai A, Yonekura L and Nagao A: Low
bioavailability of dietary epoxyxanthophylls in humans. Br J Nutr.
100:273–277. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sherr CJ and Roberts JM: Living with or
without cyclins and cyclin-dependent kinases. Genes Dev.
18:2699–2711. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Burstein E and Duckett CS: Dying for
NF-κB? Control of cell death by transcriptional regulation of the
apoptotic machinery. Curr Opin Cell Biol. 15:732–737. 2003.
|
